Skip to content

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Wet Age-related Macular Degeneration | First-time One-year Primary Efficacy and Safety Outcomes of the Phase 3 DAYBREAK Study